CPHI Milan newsletter
PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

CDMO Subsection

Insights into the latest developments in CDMO services and manufacturing.

Continue reading

Injectables Subsection

Expert perspectives on the evolving needs of injectable therapies and packaging.

Continue reading

Nasal & Pulmonary Subsection

Exploring the latest developments in inhalation technologies, respiratory delivery and sustainability

Continue reading

Advertisement

CPHI Milan
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Lifecore Biomedical

Advertisement

Solstice

INVESTINDUSTRIAL ACQUIRES PROVERIS SCIENTIFIC CORPORATION, A LEADING GLOBAL MANUFACTURER OF ANALYTICAL TESTING INSTRUMENTATION FOR THE PHARMACEUTICAL INDUSTRY

An independently managed investment subsidiary of Investindustrial Growth III SCSp (“Investindustrial”) has acquired Proveris Scientific Corporation (“Proveris”), a leader in the design and manufacture of spray and aerosol testing instrumentation, software and laboratory solutions for the pharmaceutical industry with a specialization on orally inhaled and nasal drug products (“OINDP”).

Founded by Dino J. Farina, and headquartered in Hudson, Massachusetts, Proveris has been serving the world’s leading pharmaceutical companies since 1995 and is the global provider of choice for spray characterization testing instrumentation, lab services and OINDP expertise. Proveris’ technologies are deeply embedded in customer workflows and regulatory processes, supporting reproducibility, data continuity, and long-term customer relationships. In serving a diverse and global customer base of branded and generic pharmaceutical companies, contract development organizations, device makers and regulatory agencies, Proveris’ technologies and expertise are integral to organizations for OINDP approvals in more than 30 countries.

Through its investment in and in partnership with Proveris’ management, Investindustrial aims to drive further Proveris’ expansion and build a leading pharmaceutical testing equipment group positioned for continued global growth, both through organic and acquisitive expansion in its existing markets and in adjacent pharmaceutical testing equipment categories. With a global reputation for innovation and quality and a broad international sales base, Proveris is exceptionally well positioned to serve as the ideal foundation for this ambitious growth strategy.

Building on the proven success of its affiliates in providing advisory support to companies across the equipment, automation and healthcare industries, with investments such as Arterex, Ourvita, GeneraLife, Lifebrain, and Omnia Technologies, Investindustrial brings the deep sector experience, integration capabilities, operational expertise and global presence needed to support Proveris’ continued development while preserving its science-led culture and customer focus.

Founder Dino Farina, a pioneer in the OINDP testing equipment industry, will remain with Proveris and has reinvested as a minority shareholder alongside Investindustrial, reinforcing Investindustrial’s reputation as the partner of choice for ambitious founders, entrepreneurs and family business owners.

Andrea C. Bonomi, Chairman of the Investindustrial Industrial Advisory Board, said: “Proveris represents an exceptional platform to build a global leader in specialty pharmaceutical testing equipment. We greatly admire what Dino and the team have achieved and look forward to partnering on the next phase of growth. By leveraging our industrial expertise, international reach, and strong integration capabilities, we aim to accelerate growth and expand the company’s global footprint.”

Dino Farino, Founder & CEO of Proveris, said: “Investindustrial represents everything I could hope for in a partner focused on strategic growth, investment and value creation for Proveris’ customers and the Proveris team. I am very excited for the future working with the Investindustrial team.”

Investindustrial was advised by EuroConsult, Inc. as financial advisor and White & Case LLP as legal advisors.

The sellers were advised by City Capital Advisors as exclusive financial advisor and Mirick O’Connell DeMallie & Lougee LLP as legal advisor.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Tjoapack
Aptar – 08/01/2026